Janson Pharmaceuticals incurred the following costs in 2018 related to a new cancer drug:

Research for new formulas	$	2,495,000
Development of a new formula		1,670,000
Legal and filing fees for a patent for the new formula		67,000
Total	$	4,232,000

The development costs were incurred after technological and commercial feasibility was established and after the future economic benefits were deemed probable. The project was successfully completed and the new drug was patented before the end of the 2018 fiscal year.